
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
CCR Focus |
Authors' Affiliation: Abramson Cancer Center at the University of Pennsylvania, Philadelphia, Pennsylvania
Requests for reprints: Craig B. Thompson, Abramson Cancer Center at the University of Pennsylvania, 450 BRB II/III, 421 Curie Boulevard, Philadelphia, PA 19104. Phone: 215-746-5515; Fax: 215-746-5511; E-mail: craig{at}mail.med.upenn.edu.
Abstract
Metabolic and therapeutic stresses activate several signal transduction pathways that regulate cell death and cell survival in cancer cells. Although decades of research unraveled the pathways that regulate apoptosis and allowed the development of novel diagnostic and therapeutic modalities in cancer treatment, only recently has the regulation and significance of tumor cell autophagy and necrosis become the focus of investigations. Necrosis is an irreversible inflammatory form of cell death. In contrast, autophagy is a reversible process that can contribute both to tumor cell death and survival. This review describes recent advances in understanding the regulation of autophagy and necrosis and their implications for cancer therapy. Currently available methods to measure autophagy and necrosis are highlighted. The effect of tumor cell autophagy and necrosis on host immunity is explored. Finally, therapeutic approaches that target autophagy and necrosis in cancer are described.
This article has been cited by other articles:
![]() |
D. Raina, R. Ahmad, M. D. Joshi, L. Yin, Z. Wu, T. Kawano, B. Vasir, D. Avigan, S. Kharbanda, and D. Kufe Direct Targeting of the Mucin 1 Oncoprotein Blocks Survival and Tumorigenicity of Human Breast Carcinoma Cells Cancer Res., June 15, 2009; 69(12): 5133 - 5141. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. L. Piekarz and S. E. Bates Epigenetic Modifiers: Basic Understanding and Clinical Development Clin. Cancer Res., June 15, 2009; 15(12): 3918 - 3926. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Milani, T. Rzymski, H. R. Mellor, L. Pike, A. Bottini, D. Generali, and A. L. Harris The Role of ATF4 Stabilization and Autophagy in Resistance of Breast Cancer Cells Treated with Bortezomib Cancer Res., May 15, 2009; 69(10): 4415 - 4423. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Moretti, K. W. Kim, D. K. Jung, C. D. Willey, and B. Lu Radiosensitization of solid tumors by Z-VAD, a pan-caspase inhibitor Mol. Cancer Ther., May 1, 2009; 8(5): 1270 - 1279. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Hoglund, L. M. Nilsson, L. P. Forshell, K. H. Maclean, and J. A. Nilsson Myc sensitizes p53-deficient cancer cells to the DNA-damaging effects of the DNA methyltransferase inhibitor decitabine Blood, April 30, 2009; 113(18): 4281 - 4288. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Fontanini, C. Foti, H. Potu, E. Crivellato, R. Maestro, P. Bernardi, F. Demarchi, and C. Brancolini The Isopeptidase Inhibitor G5 Triggers a Caspase-independent Necrotic Death in Cells Resistant to Apoptosis: A COMPARATIVE STUDY WITH THE PROTEASOME INHIBITOR BORTEZOMIB J. Biol. Chem., March 27, 2009; 284(13): 8369 - 8381. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. H. Kim, J. M. Coates, T. L. Bowles, G. P. McNerney, J. Sutcliffe, J. U. Jung, R. Gandour-Edwards, F. Y.S. Chuang, R. J. Bold, and H.-J. Kung Arginine Deiminase as a Novel Therapy for Prostate Cancer Induces Autophagy and Caspase-Independent Apoptosis Cancer Res., January 15, 2009; 69(2): 700 - 708. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. L. Gabai, J. A. Yaglom, T. Waldman, and M. Y. Sherman Heat Shock Protein Hsp72 Controls Oncogene-Induced Senescence Pathways in Cancer Cells Mol. Cell. Biol., January 15, 2009; 29(2): 559 - 569. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. R. Fels, J. Ye, A. T. Segan, S. J. Kridel, M. Spiotto, M. Olson, A. C. Koong, and C. Koumenis Preferential Cytotoxicity of Bortezomib toward Hypoxic Tumor Cells via Overactivation of Endoplasmic Reticulum Stress Pathways Cancer Res., November 15, 2008; 68(22): 9323 - 9330. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Longo, F. Platini, A. Scardino, O. Alabiso, G. Vasapollo, and L. Tessitore Autophagy inhibition enhances anthocyanin-induced apoptosis in hepatocellular carcinoma Mol. Cancer Ther., August 1, 2008; 7(8): 2476 - 2485. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. J. Benz Jr., D. G. Nathan, R. K. Amaravadi, and N. N. Danial Targeting the Cell Death-Survival Equation Clin. Cancer Res., December 15, 2007; 13(24): 7250 - 7253. [Full Text] [PDF] |
||||
![]() |
G. L. Verdine and L. D. Walensky The Challenge of Drugging Undruggable Targets in Cancer: Lessons Learned from Targeting BCL-2 Family Members Clin. Cancer Res., December 15, 2007; 13(24): 7264 - 7270. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Rixe and T. Fojo Is Cell Death a Critical End Point for Anticancer Therapies or Is Cytostasis Sufficient? Clin. Cancer Res., December 15, 2007; 13(24): 7280 - 7287. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |